← Back to Search

Tau PET Imaging for Neurodegenerative Disease

Phase 2 & 3
Recruiting
Led By Murray Grossman, PhD, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants will be 18 years of age or older
Participants has been diagnosed with one of the following neurodegenerative diseases: FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD- ALS
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 years
Awards & highlights

Study Summary

This trial is looking at using PET/CT to measure tau in the brain in patients with FTD and other neurodegenerative diseases.

Who is the study for?
This trial is for adults diagnosed with neurodegenerative diseases like FTD, Alzheimer's, Parkinson's, and others. Participants must be able to give informed consent themselves or through a legal representative and follow the study schedule. A recent brain MRI is required; if not available, one will be provided as part of the study.Check my eligibility
What is being tested?
The trial tests an imaging agent called 18F-AV-1451 using PET/CT scans to measure tau protein levels in the brain, which are linked to cell damage in various neurodegenerative diseases.See study design
What are the potential side effects?
Potential side effects are not specified but may include discomfort from injection of the tracer, allergic reactions to it, and typical risks associated with undergoing PET/CT scans such as exposure to radiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with a specific neurodegenerative condition.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Regional uptake
Secondary outcome measures
CSF Correlate
Changes over time
Other outcome measures
Tau protein biomarkers

Side effects data

From 2018 Phase 2 trial • 7 Patients • NCT02676843
29%
Insomnia
29%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
18F-AV-1451

Trial Design

1Treatment groups
Experimental Treatment
Group I: Positron Emission Tomography (PET/CT) Imaging of Tau Pathology in Neurodegenerative DiseaseExperimental Treatment1 Intervention
Individuals who have been diagnosed with FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD-ALS may participate in this study if they are 18 years of age or older; most participants will be receiving care at the clinical practices of the of the University of Pennsylvania and at Pennsylvania Hospital Department of Neurology. Healthy control subjects will also be recruited for this study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-AV-1451
2016
Completed Phase 2
~120

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,005 Previous Clinical Trials
42,881,933 Total Patients Enrolled
Avid RadiopharmaceuticalsIndustry Sponsor
65 Previous Clinical Trials
9,414 Total Patients Enrolled
Murray Grossman, PhD, MDPrincipal InvestigatorUniversity of Pennsylvania

Media Library

Positron Emission Tomography (PET/CT) Imaging of Tau Pathology in Neurodegenerative Disease Clinical Trial Eligibility Overview. Trial Name: NCT03143374 — Phase 2 & 3
Neurodegenerative Disease Research Study Groups: Positron Emission Tomography (PET/CT) Imaging of Tau Pathology in Neurodegenerative Disease
Neurodegenerative Disease Clinical Trial 2023: Positron Emission Tomography (PET/CT) Imaging of Tau Pathology in Neurodegenerative Disease Highlights & Side Effects. Trial Name: NCT03143374 — Phase 2 & 3
Positron Emission Tomography (PET/CT) Imaging of Tau Pathology in Neurodegenerative Disease 2023 Treatment Timeline for Medical Study. Trial Name: NCT03143374 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are currently recruiting for this clinical trial?

"The study, which was originally posted on September 1st, 2016 and last updated on October 31st, 2022, is recruiting patients."

Answered by AI

Could I potentially qualify to participate in this clinical trial?

"This study is looking for 300 participants with parkinson disease aged 18 and 100. Most importantly, candidates must meet the following criteria:Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. If the subject is unable to provide informed consent, the subject's legal representative may consent on behalf of the patient, but the patient will be asked to confirm assent.INCLUSION CRITERIA FOR NEURODEGENERATIVE SUBJECTS:Participants has been diagnosed with one of"

Answered by AI

For patients that are octogenarians, is this study still recruiting?

"In order to be included in this specific clinical trial, patients must between 18 and 100 years old. Out of the 35 clinical trials for people under 18 and 539 for people over 65, this is the only one that meets this age range."

Answered by AI

How many people are allowed to participate in this clinical trial at any one time?

"That is accurate, according to the latest information on clinicaltrials.gov. This clinical trial was initially posted on September 1st, 2016 and was updated on October 31st, 2020. The study is seeking 300 participants from 1 site."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
PET Tau - Neurodegenerative Disease Imaging
2016. "PET Tau - Neurodegenerative Disease Imaging". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03143374.
~44 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top